Abstract
Older patients with acute myeloid leukemia (AML) face a dismal prognosis. Although venetoclax-based therapy has led to improved outcomes among unfit older patients with AML, it is not curative and its efficacy and long-term outcomes among fit older patients is unclear. This review provides insights into factors that influence treatment choices among older patients with AML and what we would need to know for venetoclax-based therapy to replace standard intensive 7 + 3 induction therapy.
| Original language | English (US) |
|---|---|
| Article number | 101335 |
| Journal | Best Practice and Research: Clinical Haematology |
| Volume | 34 |
| Issue number | 4 |
| DOIs | |
| State | Published - Dec 2021 |
Keywords
- 7+3
- AML
- Acute myeloid leukemia
- Azacytidine
- CR
- Complete remission
- Intensive chemotherapy
- OS
- Overall survival
- Venetoclax
ASJC Scopus subject areas
- Oncology
- Clinical Biochemistry